{
    "2018-10-11": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Abbvie settles Humira patent disputes with Novartis unit",
                "features": {
                    "keywords": [
                        "Humira",
                        "patent",
                        "disputes",
                        "Novartis",
                        "settles"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Sandoz, AbbVie Announce Global Resolution Of Humira Patent Disputes",
                "features": {
                    "keywords": [
                        "Sandoz",
                        "AbbVie",
                        "Humira",
                        "patent",
                        "resolution"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "AbbVie stock ticks higher as Humira patent dispute with Novartis resolved",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "stock",
                        "Humira",
                        "patent",
                        "resolved"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Wall Street Analysts See Upside Potential of 3.9% in TEVA",
                "features": {
                    "keywords": [
                        "Wall Street",
                        "Analysts",
                        "TEVA",
                        "upside",
                        "potential"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales",
                "features": {
                    "keywords": [
                        "Incyte",
                        "Jakafi",
                        "demand",
                        "strong",
                        "label",
                        "expansion"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing",
                "features": {
                    "keywords": [
                        "Teva",
                        "FDA",
                        "Committee",
                        "Rituxan",
                        "Biosimilar",
                        "Nod"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Novartis Presents Data on Multiple Sclerosis Drug Gilenya",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Gilenya",
                        "Multiple Sclerosis",
                        "Data"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Analysts’ Estimates and Ratings for Novartis in October",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Estimates",
                        "Ratings",
                        "Novartis"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "A Look at the Performance of Novartis’s Alcon",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Alcon",
                        "Performance"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}